Antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in oncology, offering a way to pair the targeting precision of antibodies with the potency of small-molecule drugs.
The antibody-drug conjugate landscape is facing a critical inflection point. As it stands, manufacturing complexity could pose a threat to future innovation, despite the unmatched market demand. With ...
Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results